


Emetic Risk of Single Intravenous Antineoplastic Agents in Adults




- Atezolizumab
- Avelumab
- Bevacizumab
- Bleomycin
- Busulfan
- Cemiplimab
- 2-Chlorodeoxyadenosine
- Cladribine
- Daratumumab
- Durvalumab
- Emapalumab
- Fludarabine
- Ipilimumab
- Nivolumab
- Obinutuzumab
- Ofatumumab
- Pembrolizumab
- Pixantrone
- Polatuzumab vedotin
- Pralatrexate
- Ramucirumab
- Rituximab
- Trastuzumab
- Vinblastine
- Vincristine
- Vinorelbine



- Aflibercept
- Axicabtagene ciloleucel
- Belinostat
- Blinatumomab
- Bortezomib
- Brentuximab
- Cabazitaxel
- Carfilzomib
- Catumaxumab
- Cetuximab
- Copanlisib
- Cytarabine ≤ 1,000 mg/m²
- Decitabine
- Docetaxel
- Elotuzumab
- Enfortumab vedotin-ejfv
- Eribulin
- Etoposide
- Fluorouracil
- Gemcitabine
- Gemcitabine ozogamicin
- Inotuzumab ozogamicin
- Ixabepilone
- Methotrexate
- Mitomycin
- Mitoxantrone
- Moxetumomab pasudotox
- Nab-paclitaxel
- Necitumu mab
- Nelarabine
- Paclitaxel
- Panitumumab
- Pegylated liposomal doxorubicin
- Pemetrexed
- Pertuzumab
- Tagraxofusp-erzs
- Temsirolimus
- Topotecan
- Trastuzumab-emtansine
- Vinflunine



- Alemtuzumab
- Arsenic trioxide
- Azacitidine
- Bendamustine
- Carboplatin
- Clofarabine
- Cyclophosphamide < 1,500 mg/m²
- Cytarabine > 1,000 mg/m²
- Daun or u bi cin
- Daunorubicin and cytarabine liposome
- Doxorubicin
- Epirubicin
- Idarubicin
- . Ifosfamide
- Irinotecan
- Irinotecan liposomal injection
- Oxaliplatin
- Romidepsin
- Temozolomide*
- Thiotepa†
- Trabectedin



- Anthracycline/ cyclophosphamide combination
- Carmustine
- Cisplatin
- Cyclophosphamide ≥ 1,500 mg/m²
- Dacarbazine
- Mechlorethamine
- Streptozocin


†Classification refers to individual evidence from pediatric trials.

ASCO Guidelines

This chart is derived from recommendations in Antiemetics: ASCO Guideline Update. This is a tool based on an ASCO guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.

^{*} No direct evidence found for intravenous temozolomide; as all sources indicate a similar safety profile to the oral formulation, the classification was based on oral temozolomide.

Emetic Risk of Single Oral Antineoplastic Agents in Adults*



- 6-Thioguanine
- Acalabrutinib
- Afatinib
- Alectinib
- Alpelisib
- Axatinib
- Bexarotene
- Brigatinib
- Capecitabine
- Chlorambucil
- Cobimetinib
- Dabrafenib
- Dacomitinib
- Dasatinib
- Duvelisib
- Encorafenib
- Entrectinib
- Erdafitinib
- Erlotinib
- Estramustine
- Etoposide
- Everolimus
- Fludarabine
- Gefitinib
- Gilteritinib
- Glasdegib
- Hydroxyurea
- Ibrutinib
- Idelalisib
- Ivosidenib
- Ixazomib
- Lapatinib
- Larotrectinib

- Lenalidomide
- Lenvatinib
- Lorlatinib
- Melphalan
- Methotrexate
- Neratinib
- Nilotinib
- Olaparib
- Osimertinib
- Palbociclib
- Panobinostat
- Pazopanib
- Pexidartinib
- Pomalidomide
- Ponatinib
- Regorafenib
- Ruxolitinib
- Sonidegib
- Sorafenib
- Sunitinib
- Talazoparib
- Tazemetostat
- Tegafur-Uracil
- Thalidomide
- Topotecan
- Trametinib
- Vandetanib
- Vemurafenb
- Venetoclax
- Vismodegib
- visiliouegii
- Vorinostat
- Zanubrutinib


- Moderate or High (> 30%)
 - Abemaciclib
 - Avapritinib
 - Bosutinib
 - Cabozantinib
 - Ceritinib
 - Crizotinib
 - Cyclophosphamide
 - Enasidenib
 - Fedratinib
 - Hexamethylmelamine
 - Imatinib
 - Lenvatinib
 - Lomustine
 - Midostaurin
 - Niraparib
 - Procarbazine
 - Ribociclib
 - Rucaparib
 - Selinexor
 - TAS-102 (trifluridinetipiracil)
 - Temozolomide
 - Vinorelbine

^{*}Classified emetic potential of oral agents based on a full course of therapy and not a single dose.




This chart is derived from recommendations in Antiemetics: ASCO Guideline Update. This is a tool based on an ASCO guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.


Emetic Risk in Adults by Site of Radiation Therapy




- Extremities
- Breast



- Brain
- Head and Neck
- Thorax
- Pelvis



- Upper Abdomen
- Craniopinal Irradiation



 Total Body Irradiation

ASCO Guidelines

This chart is derived from recommendations in Antiemetics: ASCO Guideline Update. This is a tool based on an ASCO guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.